TLX591-CDx (Illuccix® in approved jurisdictions, 68 Ga-PSMA-11 ): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation ...
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Res
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...
The Director-General of the Nigeria Employers’ Consultative Association (NECA), Adewale-Smatt Oyerinde, has commended ...
Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...
Disney+ and Hulu will soon be merging into a single streaming service, with one login working for both (but you can watch ...
"I volunteered, as I was bored out of my mind anyway. I arrive at the house, and the entry gate is smashed, a section of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback